Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi Reports Improved Quarter, Again

publication date: May 28, 2008

WuXi PharmaTech Inc. reported Q1 revenues were 69% higher than year-earlier numbers at $57.1 million. However, this year’s revenue includes an $11 million contribution from the AppTec acquisition, which was closed on January 31, 2008. Without AppTec, WuXi’s revenues grew by 36%. Net income jumped 132% to $13.9 million, which works out to an earnings per ADS figure of 19 cents. WuXi reiterated its guidance of 2008 revenues in a $280 million-$300 million range. More details...

Stock Symbol: (NYSE: WX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here